The earnings call reveals a mix of positive and negative outcomes. Revenue and profit increased, driven by strong product performance and strategic investments. However, challenges such as the impact of drug price revisions, project suspensions, and revenue recognition delays were also highlighted. The overall sentiment is balanced with notable achievements and significant challenges.

Company Guidance -

Q3 2025

During the earnings call for the second quarter of fiscal year 2025, several key financial metrics were highlighted. Revenue increased by 4.6% compared to the previous year, reaching JPY 578.5 billion, driven by both domestic and overseas product sales. Operating profit rose by 3.5% to JPY 272 billion, and net income saw a 2.1% increase, totaling JPY 193.5 billion. The company noted a JPY 25.6 billion rise in revenue, with domestic sales growing by JPY 6.1 billion despite challenges like NHI drug price revisions. Overseas sales were boosted by JPY 19.7 billion due to increased export volumes and favorable exchange rates. The call also covered strategic R&D developments, including progress on projects such as orforglipron and NXT007, while announcing the discontinuation of five early-stage in-house pipeline projects to prioritize resources for higher-value endeavors. Additionally, a new JPY 80 billion research building was announced, aimed at strengthening pharmaceutical manufacturing capabilities.

Increased Revenue and Profit

In the second quarter of 2025, domestic and overseas product sales increased, resulting in a 4.6% increase in revenue, a 3.5% increase in operating profit, and a 2.1% increase in net income compared to the previous year.

Strong Performance of New Products

Sales of new products such as Phesgo, PiaSky, and Vabysmo increased by JPY 6.1 billion domestically. Overseas sales also saw a significant increase of JPY 19.7 billion, with exports of Actemra to Roche increasing significantly.

R&D Milestone Achievements

Eli Lilly announced the success of a global Phase III trial for orforglipron for type 2 diabetes. New in-house projects, MINT91 and medium molecule project AUBE00, have begun Phase I trials.

New Investments in Pharmaceutical Manufacturing

A new research building UKX at the Ukima site with a total investment of JPY 80 billion was announced to strengthen pharmaceutical manufacturing process development functions.

Chugai Pharmaceutical Co (JP:4519) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JP:4519 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 24, 2025	2025 (Q3)	67.77 / -	66.55	―	―	―
Jul 24, 2025	2025 (Q2)	74.09 / 57.83	67.98	-14.93% (-10.15)
Apr 24, 2025	2025 (Q1)	50.97 / 59.09	45.22	30.67% (+13.87)
Jan 30, 2025	2024 (Q4)	58.98 / 55.64	55.434	0.37% (+0.21)
Oct 25, 2024	2024 (Q3)	60.40 / 66.55	47.15	41.15% (+19.40)		―
Jul 25, 2024	2024 (Q2)	54.06 / 67.98	50.57	34.43% (+17.41)
Apr 24, 2024	2024 (Q1)	47.26 / 45.22	44.68	1.21% (+0.54)		―
Feb 01, 2024	2023 (Q4)	50.77 / 55.43	62.29	-11.01% (-6.86)		―
Oct 24, 2023	2023 (Q3)	48.90 / 47.15	41.21	14.41% (+5.94)		―
Jul 27, 2023	2023 (Q2)	41.46 / 50.57	44	14.93% (+6.57)		―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

JP:4519 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 24, 2025	¥7117.00	¥7238.00	+1.70%
Apr 24, 2025	¥8058.93	¥8114.99	+0.70%
Jan 30, 2025	¥6274.83	¥6261.06	-0.22%
Oct 25, 2024	¥6771.54	¥6700.33	-1.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Chugai Pharmaceutical Co (JP:4519) report earnings?

Chugai Pharmaceutical Co (JP:4519) is schdueled to report earning on Oct 24, 2025, Before Open (Confirmed).

What is Chugai Pharmaceutical Co (JP:4519) earnings time?

Chugai Pharmaceutical Co (JP:4519) earnings time is at Oct 24, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Chugai Pharmaceutical Co stock?

The P/E ratio of Chugai Pharmaceutical Co is N/A.

What is JP:4519 EPS forecast?

JP:4519 EPS forecast for the fiscal quarter 2025 (Q3) is 67.77.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing